加载中
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
收盘时
US$8.55
−US$0.05 · -0.58%
盘后
US$8.54
−US$0.01 · -0.12%
10月12日 16:03 ET
盘中时间采用ET。市场数据可能有所延迟。
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
日内区间
当前US$8.55
52周区间
当前US$8.55
盘中时间采用ET。市场数据可能有所延迟。
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
日内区间
当前US$8.55
52周区间
当前US$8.55
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 1318.5万 USD | — | 449.01万 USD | 485.37万 USD | 146.85万 USD |
| 销货成本 | 6.27万 USD | — | 9.76万 USD | 41.85万 USD | 21.75万 USD |
| 毛利 | 1312.24万 USD | — | 439.25万 USD | 443.52万 USD | 125.09万 USD |
| 研究与开发 | 1236.89万 USD | 1489.85万 USD | 2240.04万 USD | 2263.06万 USD | 2132.74万 USD |
| 销售、一般及管理费用 | 948.44万 USD | 780.93万 USD | 1227万 USD | 1529.08万 USD | 1651.19万 USD |
| 营业费用 | 2185.33万 USD | 1745.99万 USD | 2688.86万 USD | 3689.41万 USD | 3783.94万 USD |
| 利息收入 | 29.71万 USD | — | — | — | — |
| 利息支出 | 6726 USD | 1.5万 USD | 1.71万 USD | 2万 USD | 2.97万 USD |
| 折旧和摊销 | 6.27万 USD | 25.89万 USD | 33.91万 USD | 28.83万 USD | 12.67万 USD |
| 营业利润 | −866.83万 USD | −1745.99万 USD | −2249.61万 USD | −3245.89万 USD | −3658.84万 USD |
| 净利润 | −837.79万 USD | −1730.73万 USD | −2973.61万 USD | −2403.67万 USD | −3619.83万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$47.50
上涨空间 455.56%评级样本有限，仅3项
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年8月12日 | 1:50 | — | — |
股票拆分 | 2022年8月31日 | 1:25 | — | — |
股票拆分 | 2010年9月27日 | 1:10 | — | — |
股票拆分 | 1997年9月8日 | 1:4 | — | — |
股票拆分 | 1996年7月22日 | 1:10 | — | — |
已生效 2025年8月12日
1:50
已生效 2022年8月31日
1:25
已生效 2010年9月27日
1:10
已生效 1997年9月8日
1:4
已生效 1996年7月22日
1:10
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
